NCT07110753

Brief Summary

A growing number of people are living with the (long-term) consequences of cancer and its treatment, which can negatively affect their quality of life. This study aims to assess the effect of a combined lifestyle intervention for patients with cancer on quality of life.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
244

participants targeted

Target at P75+ for not_applicable cancer

Timeline
12mo left

Started Aug 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress45%
Aug 2025Apr 2027

First Submitted

Initial submission to the registry

June 25, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 8, 2025

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2027

Last Updated

August 8, 2025

Status Verified

July 1, 2025

Enrollment Period

1.6 years

First QC Date

June 25, 2025

Last Update Submit

July 31, 2025

Conditions

Keywords

cancercombined lifestyle interventionquality of lifepositive health

Outcome Measures

Primary Outcomes (1)

  • Health Related Quality of Life

    Summary score of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). This questionnaire consists of five functioning scales (physical, emotional, role, cognitive and social functioning), three symptom scales (fatigue, nausea \& vomiting) and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The EORTC QLQ-C30 summary score ranges from 0 to 100, with higher scores indicating better health-related quality of life. This summary score is calculated as the mean of all scale scores (excluding global QoL and financial difficulties).

    Measured at 0, 6 and 12 months

Secondary Outcomes (18)

  • Health-Related Quality of Life - separate functioning and symptom scales

    Measured at 0, 6 and 12 months

  • Cancer-related fatigue

    Measured at 0, 6 and 12 months

  • Sleep Hygiene

    Measured at 0, 6 and 12 months

  • Positive Health

    Measured at 0, 6 and 12 months

  • Height

    Measured at 0 and 6 months

  • +13 more secondary outcomes

Study Arms (2)

Intervention group

EXPERIMENTAL

Following a combined lifestyle intervention for 12 months

Behavioral: combined lifestyle intervention focusing on various lifestyle components, delivered by a lifestyle coach and oncology nurse

Control group

PLACEBO COMPARATOR

Receiving four online group sessions with a lifestyle coach and all educational materials after the intervention period of 6 months.

Behavioral: short online lifestyle intervention by lifestyle coach and educational materials after 6 months

Interventions

The combined lifestyle intervention focuses on various lifestyle components, including nutrition, physical activity, sleep, stress and sense of purpose, and is structured around the process of behaviour change. It is delivered by a lifestyle coach in collaboration with an oncology nurse.

Intervention group

The control group receives 4 online group sessions from a lifestyle coach and all educational materials after 6 months of intervention

Control group

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be diagnosed with an invasive or hematological cancer type and either within five years post-primary treatment with curative intent OR having advanced cancer (stage IV) with a prolonged life expectancy (chronic cancer patients) . Primary treatment in this context, includes among others surgery (\> 3 months ago), radiotherapy, and/or chemotherapy or a stem cell transplant in case of hematological cancers.
  • Report a reduced HRQoL, i.e., a low score on at least 2 of the functioning scales and/or the symptom scale fatigue of the EORTC-QLQ-30 based on the thresholds of clinical importance of Giesinger et al. (2020)
  • Be 40 years of age or older. The investigators have chosen this cut-off because they believe that younger cancer patients (AYA's) face different challenges and should not be mixed with the average older patient. This approach ensures greater homogeneity within the study population.
  • Be able to speak and understand Dutch

You may not qualify if:

  • Following, or planned to follow a combined lifestyle intervention (i.e., one of the existing interventions for overweight) during the intervention period
  • Patients in the terminal phase (life expectancy \< 3 months)
  • Mental or behavioural problems that hinder participating in group lifestyle coaching indicated by the health care professional who is referring to GLINK or by the study team
  • Any circumstances that would impede ability to give informed consent or adherence to study requirements as determined by the study team or treating physician

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UMC Utrecht

Utrecht, Netherlands

RECRUITING

Related Links

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Kristel van Asselt, PhD, MD

    UMC Utrecht

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Anna Manshanden, MSc

CONTACT

Evelyn Monninkhof, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Epidemiologist and general practitioner

Study Record Dates

First Submitted

June 25, 2025

First Posted

August 8, 2025

Study Start

August 1, 2025

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

April 15, 2027

Last Updated

August 8, 2025

Record last verified: 2025-07

Locations